LifeSci Capital initiated coverage of Candel Therapeutics (CADL) with an Outperform rating and $16 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Pulendran to Candel’s RAB
- Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
- Candel Therapeutics Secures $130M Loan for Trials
- Candel Therapeutics enters into $130M term loan facility
- Candel Therapeutics announces interim data from phase 1b CAN-3110 trial